Recurrent Colorectal Liver Metastases: Upfront Local Treatment versus Neoadjuvant Systemic Therapy Followed by Local Treatment (COLLISION RELAPSE): Study Protocol of a Phase III Prospective Randomized Controlled Trial.
Madelon Dijkstra, Babette I Kuiper, Hannah H Schulz, Susan van der Lei, Robbert S Puijk, Danielle J W Vos, Florentine E F Timmer, Hester J Scheffer, Tineke E Buffart, M Petrousjka van den Tol, Birgit I Lissenberg-Witte, Rutger-Jan Swijnenburg, Kathelijn S Versteeg, Martijn R Meijerink, COLLISION Trial Group
Cardiovasc Intervent Radiol 47(2) 253-262
摘要
摘要
PURPOSE: The objective of the COLLISION RELAPSE trial is to prove or disprove superiority of neoadjuvant systemic therapy followed by repeat local treatment (either thermal ablation and/or surgical resection), compared to repeat local treatment alone, in patients with at least one recurrent locally treatable CRLM within one year and no extrahepatic disease. METHODS: A total of 360 patients will be included in this phase III, multicentre randomized controlled trial. The primary endpoint is overall survival. Secondary endpoints are distant progression-free survival, local tumour progression-free survival analysed per patient and per tumour, systemic therapy-related toxicity, procedural morbidity and mortality, length of hospital stay, pain assessment and quality of life, cost-effectiveness ratio and quality-adjusted life years. DISCUSSION: If the addition of neoadjuvant systemic therapy to repeat local treatment of CRLM proves to be superior compared to repeat local treatment alone, this may lead to a prolonged life expectancy and increased disease-free survival at the cost of possible systemic therapy-related side effects. LEVEL OF EVIDENCE: Level 1, phase III randomized controlled trial. TRIAL REGISTRATION: NCT05861505. May 17, 2023.
KM 提取结果
0 个 Figure · 0 个 KM 面板